Effective strategies to identify postmenopausal women at risk of osteoporosis

Geriatrics

Volumn 62, Issue 11, 2007, Pages 22-30

  Levine, Jeffrey P ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonates; Fracture; Fracture risk; Osteoporosis; Postmenopausal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FEMRING; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECLAST; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

AGING; ALCOHOL CONSUMPTION; BONE DENSITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FRAGILITY FRACTURE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; REVIEW; RISK FACTOR; VERTEBRA FRACTURE;

ADRENAL CORTEX HORMONES; ADULT; AGED; BODY MASS INDEX; BONE DENSITY; DIPHOSPHONATES; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; LONG-TERM CARE; MASS SCREENING; MIDDLE AGED; MOBILITY LIMITATION; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SPINAL FRACTURES;

EID: 36448954224     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Solomon DH, Morris C, Cheng H, et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005;80(2):194-202.
2. Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164(10):1113-1120.
3. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
4. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
5. Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone. 2003;32(1):78-85.
6. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists m ical guidelines for clinical practice for the prevention and treatment of post-menopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9(6):544-564.
7. Saag KG, Morgan SL, Coa X. Bone Health and Disease. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology. 15th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:2487.
8. Marshall J, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996:312(7041):1254-1259.
9. Lindsay R, Pack S, Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int. 2005;16(3):306-312.
10. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721-739.
11. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320-323.
12. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-382.
13. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155-162.
14. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc. 2004;52(9):1479-1486.
15. American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. J Am Geriatr Soc. 2001;49(5):664-672.
16. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-1936.
17. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
18. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12(7):519-528.
19. International Osteoporosis Foundation. Osteoporosis in the EU: Improving the Assessment of Fracture Risk. Available at: http://www.iofbonehealth.org/ download/osteofound/filemanager/publications/pdf/eu-report-2006.pdf. Accessed October 23, 2007.
20. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137(6):526-528.
21. Leib ES, Lewiecki EM, Binkley N, et al. Official positions of the International Society for Clinical Densitometry. South Med J. 2004;97(1):107-110.
22. Bubbear J, Keen R. Clinical management and algorithms in osteoporosis. Hosp Med. 2003;64(9):512-516.
23. National Institutes of Health Consensus Development Conference. Optimal calcium intake. NIH Consens Statement 1994;12(4):1-31.
24. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257-2264.
25. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1-2):13-19.
26. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343(21):1506-1513.
27. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin. 2004;20(4):433-439.
28. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74(2):129-135.
29. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-1352.
30. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83-91.
31. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endrocrinol Metab. 2000;85(11):4118-4124.
32. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone. 2005;37(5):651-654.
33. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007:356(18):1809-1822.
34. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.
35. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002;162(10):1140-1143.
36. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med. 2000;109(4):267-276.
37. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535- 1541.
38. Cranney A, Guyatt G, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570-578.
39. McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333-340.
40. Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249.
41. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753-761.
42. American Dental Association. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. August 2006. Available at: http://jada.ada.org/cgi/content/full/137/8/1144. Accessed October 23, 2007.
43. American College of Rheumatology Hotline. Bisphosphonate-associated osteonecrosis of the jaw. http://www.rheumatology.org/publications/hotline/ 0606onj.asp. Accessed October 23, 2007.
44. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-645.
45. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125-137.
46. Evista [package insert]. Indianapolis, IN: Eli Lilly & Co; 2003.
47. Miacalcin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, 2003.
48. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
49. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
50. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
51. Forteo [package insert]. Indianapolis, IN: Eli Lilly & Co; 2004.
52. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
53. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10(2):42-45.
54. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003-1008.
55. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209-216.